Not yet recruiting
The PRECISE-DIET Trial
NCT07937891· Steno Diabetes Center Copenhagen· Source
Not yet recruiting
dApagliflozin SC0062 and Prevention of Renal Injury; a Randomized Evaluation
NCT06072326· Phase 2· University Medical Center Groningen· Source
Not yet recruiting
AMBITION 3: A Research Study Investigating How Well Zenagamtide at Higher Dose Levels Lowers Blood Sugar and Body Weight Compared to Semaglutide in People With Type 2 Diabetes Treated With Metformin, SGLT2i, or Both
NCT07931573· Phase 3· Novo Nordisk A/S· Source
Recruiting
A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity
NCT07843498· Phase 3· Hoffmann-La Roche· Source
Recruiting
Exploring Skin Barrier Function, Recurrence of Diabetes Device-Related Contact Dermatitis, and Evaluation of Hydrocolloid and Silicone-Based Patches for Its Prevention in Children and Adolescents With Type 1 Diabetes
NCT07767461· Steno Diabetes Center Copenhagen· Source
Not yet recruiting
Effects of semaglutide as add-on therapy to sulfonylurea on plasma glucose in individuals with HNF1A- and HNF4A-MODY – A Steno MODERN-MODY project (MM-SEMA)
2025-523414-89-00· Phase 2· Steno Diabetes Center Copenhagen· Source
Recruiting
A Study to Evaluate Effect of AZD6234 as an Adjunct to Incretin-based Therapies in Adult Participants With Obesity or Overweight With Weight-related Comorbidity With or Without Type 2 Diabetes Mellitus
NCT07776509· Phase 3· AstraZeneca· Source
Recruiting
A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease.
NCT07753993· Phase 3· AstraZeneca· Source
Recruiting
Evaluation of the Safety and Performance of the Novel Medtronic Experimental Automated Insulin Delivery System (NMX8) in People Living With Diabetes (NEXUS)
NCT07227805· Medtronic MiniMed, Inc.· Source
Recruiting
A Phase III Study to Investigate the Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes Mellitus
NCT07662109· Phase 3· AstraZeneca· Source
Recruiting
A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus and Impaired Renal Function on Background Dapagliflozin
NCT07662135· Phase 3· AstraZeneca· Source
Not yet recruiting
Automated Insulin Delivery Versus Daily Injections for Hospital Diabetes Care
NCT07645079· Steno Diabetes Center Copenhagen· Source
Recruiting
Changing Outpatient Diabetes Care With Remote-Patient-Monitoring: A Real World Evidence Study With Pre-Post Comparison
NCT07617519· Steno Diabetes Center Copenhagen· Source
Recruiting
The Postprandial Hypo-Avoid Study
NCT07427251· Phase 4· Steno Diabetes Center Copenhagen· Source
Recruiting
Up-titration of sulfonylurea (SU) in individuals with HNF1A- and HNF4A-MODY – A Steno MODERN-MODY project (MM-SUUP)
2025-524679-22-00· Phase 2· Steno Diabetes Center Copenhagen· Source
Recruiting
The POST-PRANDIAL HYPO-AVOID STUDY
Low-Dose Glucagon and Automated Insulin Delivery for Prevention of Spontaneous Exercise-Induced
Hypoglycemia in People with Type 1 Diabetes
2025-523996-45-00· Phase 4· Steno Diabetes Center Copenhagen· Source
Recruiting
Digital Support for Reducing Salt Intake Among Patients With Diabetic Kidney Disease: Protocol for a Controlled Clinical Trial
NCT07485075· Steno Diabetes Center Copenhagen· Source
Not yet recruiting
Steno780G Follow-up Study
NCT07474155· Steno Diabetes Center Copenhagen· Source
Recruiting
Disentangling the Effect of Brain Insulin Resistance on Brain Health
NCT07374705· Henrik Bo Wiberg Larsson· Source
Recruiting
Non-alcoholic Fatty Liver Disease in Low Birth Weight Individuals
NCT05842850· Steno Diabetes Center Copenhagen· Source
Recruiting
Automated Insulin Delivery Versus Usual Insulin Treatment Modality Before and During Pregnancy in Women With Type 1 Diabetes
NCT07240012· Copenhagen University Hospital, Rigshospitalet· Source
Recruiting
SAFety and Efficacy of Human Anti-thymocyte ImmunoGlobUlin SAB-142 ARresting Progression of Type 1 Diabetes
NCT07187531· Phase 2· SAb Biotherapeutics, Inc.· Source
Enrolling by invitation
Urinary Proteomics to Guide Early Intervention to Prevent Complications in Type 2 Diabetes - a Feasibility Study
NCT06954090· Phase 4· Steno Diabetes Center Copenhagen· Source
Active, not recruiting
Precision Nutrition Versus Standard Dietary Care: Continuous Glucose Monitoring as a Tool for Guided Nutrition Care in Type 2 Diabetes - The PRECISE-DIET Trial. -A Pilot Study
NCT06832059· Steno Diabetes Center Copenhagen· Source
Active, not recruiting
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants with Atherosclerotic Cardiovascular Disease and Overweight or Obesity (MARITIME-CV)
2024-516652-18-00· Phase 3· Amgen Inc.· Source
Not yet recruiting
Semaglutide Treatment in Type 1 Diabetes
NCT06909006· Phase 3· Nordsjaellands Hospital· Source
Recruiting
A Feasibility Study of Optimal Non-Pharmacological Lifestyle Modifications in People With Type 2 Diabetes
NCT07262788· Steno Diabetes Center Copenhagen· Source
Active, not recruiting
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
NCT07037433· Phase 3· Amgen· Source
Recruiting
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
NCT07064473· Phase 3· Boehringer Ingelheim· Source
Recruiting
CKD-bioMatch: A biomarker-targeted clinical trial to optimize treatment for patients with chronic kidney disease
2023-507449-27-01· Phase 4· Steno Diabetes Center Copenhagen· Source
Recruiting
A Biomarker-targeted Clinical Trial to Optimize Treatment for Patients With Chronic Kidney Disease
NCT07239570· Phase 4· Peter Rossing· Source
Recruiting
The Role of the Amylin Analogue Cagrilintide in Bone Metabolism
NCT07010432· Phase 1· Novo Nordisk A/S· Source
Recruiting
Finerenone Treatment for Diabetic Cardiovascular Autonomic Neuropathy: the FibroCAN Study
NCT06906081· Phase 2· Peter Rossing· Source
Active, not recruiting
A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight
NCT06914895· Phase 3· Eli Lilly and Company· Source
Recruiting
Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin
NCT06677060· Phase 3· AstraZeneca· Source
Active, not recruiting
Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight
NCT06858839· Phase 3· Amgen· Source
Recruiting
A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure
NCT06742723· Phase 3· AstraZeneca· Source
Not yet recruiting
Prevention of Chronic Kidney Disease(CDK) Progression in Type 1 Diabetes With Long Term Use of Sodium-Glucose-coTransporter Inhibitors Avoiding Kidney hypOxia
NCT06147232· Phase 2· Steno Diabetes Center Copenhagen· Source
Recruiting
A Pragmatic Trial Comparing Empagliflozin and Dapagliflozin Through Cluster Randomization Embedded in the Electronic Health Record
NCT06642272· Phase 4· Herlev and Gentofte Hospital· Source
Recruiting
The Evaluation of the Drug R3R01 for the Excretion of Protein in the Urine in Patients With Diabetic Kidney Disease.
NCT06600412· Phase 2· River 3 Renal Corp.· Source
Recruiting
Kidney ABC
2024-511484-29-00· Phase 2· River 3 Renal Corp.· Source
Recruiting
The Effects of Tirzepatide in People With Overweight/Obesity and Coronary Artery Disease
NCT06606821· Phase 4· Tina Vilsbøll· Source
Active, not recruiting
EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)
NCT06531824· Phase 3· Boehringer Ingelheim· Source
Recruiting
A Trial of Three- and Seven-days Insulin Infusions Set
NCT06532461· Steno Diabetes Center Copenhagen· Source
Recruiting
New treatments to reduce cardiovascular disease in type 1 diabetes
2023-505794-32-04· Phase 3· Steno Diabetes Center Copenhagen· Source
Recruiting
Multifactorial Intervention to Reduce Cardiovascular Disease in Type 1 Diabetes
NCT06082063· Phase 3· Steno Diabetes Center Copenhagen· Source
Recruiting
Automated Insulin Delivery for Type 1 Diabetes - Beyond Glucose Metrics
NCT06469593· Steno Diabetes Center Copenhagen· Source
Recruiting
Cognitive Screening and Multidomain Intervention Targeting Cognitive Decline in Type 2 Diabetes (The Brain Care Study)
NCT07250789· Steno Diabetes Center Copenhagen· Source
Active, not recruiting
A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure.
NCT06268873· Phase 3· AstraZeneca· Source
Recruiting
Restricted Eating Time in the Treatment of Type 2 Diabetes
NCT06152588· Steno Diabetes Center Copenhagen· Source
Showing 50 of 62.